ISR: Background, evolution and implementation, with specific consideration for ligand-binding assays

Bioanalysis

Volumn 6, Issue 3, 2014, Pages 393-402

  Findlay, John W A ^a   Kelley, Marian M ^b  

^a MKelley Consulting LLC ^*

^b MKelley Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; BIOMARKER ASSAY; CHROMATOGRAPHY; EVALUATION STUDY; GOVERNMENT REGULATION; HUMAN; IMMUNOGENECITY ASSAY; ISR ANALYSIS; NONHUMAN; RECEPTOR BINDING ASSAY; REVIEW; VALIDATION STUDY;

BIOLOGICAL ASSAY; GOVERNMENT REGULATION; HUMANS; LIGANDS; SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84893410428     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.339     Document Type: Review

References (44)

1. Shah VP, Midha KK, Dighe S et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Pharm. Res. 9(4), 588-592 (1992
2. Shah VP, Midha KK, Findlay JWA et al. Bioanalytical method validation-A revisit with a decade of progress. Pharm Res. 17(12), 1551-1557 (2000
3. Miller KJ, Bowsher RR, Celniker A et al. Workshop on bioanalytical methods validation for macromolecules: Summary report. Pharm. Res. 18(9), 1373-1383 (2001
4. Findlay JWA, Smith WC, Lee JW et al. Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21, 1249-1273 (2000
5. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry: Bioanalytical Method Validation. US FDA, Rockville, MD, USA (2001
6. DeSilva B, Smith W, Weiner R et al. Recommendations for bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003
7. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006
8. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008
9. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Bioanalytical Method Validation. European Medicines Agency, London, UK (2011
10. Van Amsterdam P, Companjen A, Brudny-Kloeppel M et al. The European Bioanalysis Forum community's evaluation, interpretation and implementation of the European Medicines Agency guideline on bioanalytical method validation. Bioanalysis 5(6), 645-659 (2013
11. Boterman M, Doig M, Breda M et al. Recommendations on the interpretation of the new European Medicines Agency guideline on bioanalytical method validation by Global CRO Council for Bioanalysis (GCC). Bioanalysis 4(6), 651-660 (2012
12. Viswanathan CT. Incurred sample reanalysis: A global transformation. Bioanalysis 3(23), 2601-2602 (2011).
13. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007
14. Fast DM, Kelley M, Viswanathan CT et al. Workshop report and follow-up-AAPS workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples-implications of Crystal City recommendations. AAPS J. 11(2), 238-241 (2009
15. Timmerman P, Leudtke S, van Amsterdam P et al. Incurred sample reproducibility: Views and recommendations by the European Bioanalysis Forum. Bioanalysis 1(6), 1049-1056 (2009).
16. Lowes S, Jersey J, Shoup R et al. Recommendations on: Internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis. Bioanalysis 3(12), 1323-1332 (2011).
17. DeSilva B, Garofolo F, Rocci M et al. 2012 White paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis 4(18), 2213-2226 (2012
18. Canadian Health Ministry. Guidance for Industry. Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part A: Oral Dosage Formulations Used for Systemic Effects. Minister of Health, Health Canada, Ottawa, Canada (1992
19. Canadian Health Ministry. Guidance for Industry. Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part B: Oral Modified Release Formulations Used for Systemic Effects. Minister of Health, Health Canada, Ottawa, Canada (1996
20. Canadian Health Ministry. Notice for Industry-Removal of Requirement for 15% Random Replicate Samples. Minister of Health, Health Canada, Ottawa, Canada (2003
21. Van Amsterdam P, Arnold M, Bansal S et al. Building the Global Bioanalysis Consortium-working towards a functional globally acceptable and harmonized guideline on bioanalytical method validation. Bioanalysis 2(11), 1801-1803 (2010
22. Savoie N, Booth BP, Bradley T et al. The 2nd Calibration and Validation Group Workshop on recent issues in Good Laboratory Practice bioanalysis. Bioanalysis 1(1), 19-30 (2009
23. Rocci ML Jr, Devanarayan V, Haughey DB et al. Confirmatory reanalysis of incurred bioanalytical samples. AAPS J. 9(3), E336-E343 (2007
24. Ministry of Health, Labour and Welfare. Draft Guideline on Bioanalytical Method Validation in Pharmaceutical Development. Ministry of Health, Labour and Welfare, Tokyo, Japan (2013).
25. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i, 307-310 (1986
26. Lytle FE, Julian RK, Tabert AM. Incurred sample reanalysis: Enhancing the Bland-Altman approach with tolerance intervals. Bioanalysis 1(4), 706-714 (2009
27. Tang D, Zhong D. Regulated bioanalysis and the desire for harmonized regulations in China. Bioanalysis 2(12), 1913-1919 (2010
28. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry: Bioanalytical Method Validation (DRAFT). US FDA, Rockville, MD, USA (2013
29. Hoffman D. Statistical considerations for assessment of bioanalytical incurred sample reproducibility. AAPS J. 11(3), 570-580 (2009).
30. Meng M, Reuschel S, Bennett P. Identifying trends and developing solutions for incurred sample analysis failure investigations in a bioanalytical CRO. Bioanalysis 3(4), 449-465 (2011
31. Tan A, Gagnon-Carignan S, Lachance S et al. Beyond successful ISR: Case-by-case investigations for unmatched reassay results when ISR passed. Bioanalysis 3(9), 1031-1038 (2011
32. Garofolo P, Bergeron A, Savoie N. How to manage having no incurred sample reanalysis evaluation failures. Bioanalysis 3(9), 935-938 (2011
33. Rocci ML, Collins E, Wagner-Caruso KE et al. Investigation and resolution of incurred sample reanalysis failures: Two case studies. Bioanalysis 3(9), 993-1000 (2011
34. Yadav M, Shrivastav PS. Incurred sample reanalysis (ISR): A decisive tool in bioanalytical research. Bioanalysis 3(9), 1007-1024 (2011
35. Findlay JWA. Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution. AAPS J. 10(3), 433-434 (2008
36. Findlay JWA. Specificity of bioanalytical methods for pharmacokinetic supportof biological macromolecular therapeutics is important. Bioanalysis 3(6), 567-569 (2011
37. Thway TM, Macaraeg CR, Calamba D et al. Bioanalytical method requirements and statistical considerations in incurred sample reanalysis for macromolecules. Bioanalysis 2(9), 1587-1596 (2010
38. Thway TM, Eschenberg M, Calamba D et al. Assessment of incurred sample reanalysis for macromolecules to evaluate bioanalytical method robustness; effects from imprecision. AAPS J. 13(2), 291-298 (2011).
39. Sailstad JM, Salfen BE, Bowsher RR. Incurred sample reanalysis: Failures in macromolecule analysis-insight into possible causes. Bioanalysis 3(9), 1001-1006 (2011
40. Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies 2, 113-129 (2013
41. Kaur S, Xu K, Saad OM et al. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013
42. Gorovits B, Alley SC, Bilic S et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists antibody-drug conjugate working group position paper. Bioanalysis 5(9), 997-1006 (2013
43. Stevenson L, Garofolo F, DeSilva B et al 2013 White paper on recent issues in bioanalysis: 'hybrid'-The best of LBA & LC-MS. Bioanalysis 5(23), 2903-2918 (2013
44. Kelley M. Incurred sample reanalysis: It's just a matter of good scientific practice. Bioanalysis 3(9), 931-932 (2011